[go: up one dir, main page]

SMT201400161B - Nuove forme poliformiche di sale di idrocloruro di3-(1-[[3-[5-1-metil-piperidin-4il metossi)-pirimidin-2-il]-benzil]]-6-osso-1,6-didro-piridazin-3-il-benzonitrile e procedimenti per la sua produzione - Google Patents

Nuove forme poliformiche di sale di idrocloruro di3-(1-[[3-[5-1-metil-piperidin-4il metossi)-pirimidin-2-il]-benzil]]-6-osso-1,6-didro-piridazin-3-il-benzonitrile e procedimenti per la sua produzione

Info

Publication number
SMT201400161B
SMT201400161B SM201400161T SM201400161T SMT201400161B SM T201400161 B SMT201400161 B SM T201400161B SM 201400161 T SM201400161 T SM 201400161T SM 201400161 T SM201400161 T SM 201400161T SM T201400161 B SMT201400161 B SM T201400161B
Authority
SM
San Marino
Prior art keywords
poliform
didro
benzonitrile
pyridazine
pyrimidin
Prior art date
Application number
SM201400161T
Other languages
English (en)
Italian (it)
Inventor
Dieter Dorsch
Oliver Schadt
Frank Stieber
Axel Becker
Christoph Saal
Clemens Kuehn
Heinz-Hermann Bokel
Christina Donini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201400161(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SMT201400161B publication Critical patent/SMT201400161B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SM201400161T 2009-01-08 2014-10-30 Nuove forme poliformiche di sale di idrocloruro di3-(1-[[3-[5-1-metil-piperidin-4il metossi)-pirimidin-2-il]-benzil]]-6-osso-1,6-didro-piridazin-3-il-benzonitrile e procedimenti per la sua produzione SMT201400161B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09000140 2009-01-08
EP09764204.5A EP2373640B1 (en) 2009-01-08 2009-12-04 Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
PCT/EP2009/008684 WO2010078897A1 (en) 2009-01-08 2009-12-04 Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Publications (1)

Publication Number Publication Date
SMT201400161B true SMT201400161B (it) 2015-01-15

Family

ID=41572530

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201400161T SMT201400161B (it) 2009-01-08 2014-10-30 Nuove forme poliformiche di sale di idrocloruro di3-(1-[[3-[5-1-metil-piperidin-4il metossi)-pirimidin-2-il]-benzil]]-6-osso-1,6-didro-piridazin-3-il-benzonitrile e procedimenti per la sua produzione

Country Status (31)

Country Link
US (3) US8710058B2 (es)
EP (1) EP2373640B1 (es)
JP (2) JP5719781B2 (es)
KR (2) KR101730791B1 (es)
CN (1) CN102272121B (es)
AR (1) AR074996A1 (es)
AU (1) AU2009336839B2 (es)
BR (1) BRPI0922642B8 (es)
CA (4) CA3014648C (es)
CL (1) CL2011001356A1 (es)
CO (1) CO6400191A2 (es)
CY (1) CY1115631T1 (es)
DK (1) DK2373640T3 (es)
EA (1) EA019342B1 (es)
EC (1) ECSP11011248A (es)
ES (1) ES2522629T3 (es)
HR (1) HRP20140908T1 (es)
IL (1) IL213829A0 (es)
MX (3) MX350894B (es)
MY (1) MY160017A (es)
NZ (1) NZ594404A (es)
PE (2) PE20141317A1 (es)
PL (1) PL2373640T3 (es)
PT (1) PT2373640E (es)
SG (2) SG10201504735QA (es)
SI (1) SI2373640T1 (es)
SM (1) SMT201400161B (es)
TW (1) TWI475997B (es)
UA (1) UA106220C2 (es)
WO (1) WO2010078897A1 (es)
ZA (1) ZA201105782B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141317A1 (es) 2009-01-08 2014-09-26 Merck Patent Gmbh Nuevas formas polimorficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparacion
CN104203243A (zh) * 2012-03-19 2014-12-10 默克专利股份公司 具有抗肿瘤活性的6-氧代-1,6-二氢-哒嗪衍生物与其他抗肿瘤化合物的组合
RS56485B1 (sr) * 2012-11-02 2018-01-31 Merck Patent Gmbh 6-okso-1,6-dihidro-piridazin derivat za upotrebu u tretmanu hepatocelularnog karcinoma (hcc)
KR20160099724A (ko) * 2014-01-07 2016-08-22 메르크 파텐트 게엠베하 신장 세포 암종 (rcc) 치료를 위해 사용되는 6-옥소-1,6-디히드로-피리다진 유도체
US10532052B2 (en) 2014-12-12 2020-01-14 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor
ES2922637T3 (es) * 2015-04-03 2022-09-19 Impact Therapeutics Shanghai Inc Forma de dosificación farmacéutica sólida de inhibidor de PARP y aplicación de forma de dosificación farmacéutica sólida de inhibidor de PARP
WO2016192831A1 (en) 2015-05-29 2016-12-08 Merck Patent Gmbh Compositions of anions and cations with pharmacological activity
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
EP3786155B1 (en) * 2018-04-26 2023-08-16 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
PL3996688T3 (pl) * 2019-07-10 2024-02-12 Merck Patent Gmbh Preparat farmaceutyczny
EP4083040A4 (en) 2020-01-21 2024-04-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. IRAQ4 INHIBITOR CRYSTAL AND PREPARATION METHOD THEREFOR
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
KR102489160B1 (ko) 2021-05-26 2023-01-18 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
WO2022250350A1 (ko) 2021-05-26 2022-12-01 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
IL309014A (en) 2021-06-04 2024-01-01 Merck Patent Gmbh Compounds for the treatment of glioblastoma
CN114394957B (zh) * 2021-12-24 2023-05-09 武汉九州钰民医药科技有限公司 Met抑制剂盐酸特泊替尼的制备方法
KR20230155324A (ko) 2022-05-03 2023-11-10 주식회사 이노큐어테라퓨틱스 피페리딘디온 유도체
CN116768868B (zh) * 2023-08-15 2023-12-08 云南省药物研究所 一种哒嗪酮硫代衍生物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094909B2 (en) * 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US7169932B2 (en) * 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
ATE554771T1 (de) * 2003-08-19 2012-05-15 Pharmaton Sa Multivitaminsirup für kinder und junge erwachsene
WO2005026114A1 (en) * 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
TW200616634A (en) * 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
US20070249637A1 (en) * 2004-10-21 2007-10-25 Collins Michael R Inhibitors Of Hepatitis C Virus Protease, And Compositions And Treatments Using The Same
WO2006048744A1 (en) * 2004-11-02 2006-05-11 Pfizer Inc. Methods of preparing indazole compounds
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
CL2007001166A1 (es) * 2006-04-26 2008-01-25 Piramed Ltd Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
US7820812B2 (en) * 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) * 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
PE20141317A1 (es) * 2009-01-08 2014-09-26 Merck Patent Gmbh Nuevas formas polimorficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparacion

Also Published As

Publication number Publication date
PT2373640E (pt) 2014-09-30
EA019342B1 (ru) 2014-02-28
EA201101039A1 (ru) 2012-02-28
EP2373640A1 (en) 2011-10-12
CN102272121B (zh) 2014-12-10
US20140200221A1 (en) 2014-07-17
UA106220C2 (ru) 2014-08-11
JP2012514609A (ja) 2012-06-28
BRPI0922642B8 (pt) 2021-05-25
CA3014648A1 (en) 2010-07-15
CA2749012C (en) 2017-01-31
HK1164856A1 (en) 2012-09-28
CA2949515C (en) 2018-10-23
MX2011007322A (es) 2011-07-29
US20110269767A1 (en) 2011-11-03
TWI475997B (zh) 2015-03-11
CO6400191A2 (es) 2012-03-15
HRP20140908T1 (hr) 2014-11-07
DK2373640T3 (da) 2014-10-06
CN102272121A (zh) 2011-12-07
NZ594404A (en) 2013-04-26
TW201029655A (en) 2010-08-16
CA2749012A1 (en) 2010-07-15
PE20120474A1 (es) 2012-05-04
PE20141317A1 (es) 2014-09-26
ES2522629T3 (es) 2014-11-17
SG10201504735QA (en) 2015-07-30
EP2373640B1 (en) 2014-07-30
KR101829595B1 (ko) 2018-02-14
ECSP11011248A (es) 2011-10-31
ZA201105782B (en) 2012-04-25
CA3014648C (en) 2021-06-01
JP2015038148A (ja) 2015-02-26
PL2373640T3 (pl) 2014-12-31
AR074996A1 (es) 2011-03-02
CA3097370A1 (en) 2010-07-15
BRPI0922642B1 (pt) 2020-09-29
BRPI0922642A2 (pt) 2016-01-05
AU2009336839A1 (en) 2011-08-25
AU2009336839A8 (en) 2011-09-08
MX363852B (es) 2019-04-05
IL213829A0 (en) 2011-07-31
US9308205B2 (en) 2016-04-12
SG172831A1 (en) 2011-08-29
AU2009336839B2 (en) 2015-12-24
KR20110111472A (ko) 2011-10-11
MX363848B (es) 2019-04-05
MX350894B (es) 2017-09-22
WO2010078897A1 (en) 2010-07-15
US9289427B2 (en) 2016-03-22
MY160017A (en) 2017-02-15
US20150148351A1 (en) 2015-05-28
KR20170047408A (ko) 2017-05-04
CY1115631T1 (el) 2017-01-04
JP5860126B2 (ja) 2016-02-16
US8710058B2 (en) 2014-04-29
SI2373640T1 (sl) 2014-11-28
KR101730791B1 (ko) 2017-04-27
CL2011001356A1 (es) 2011-09-30
JP5719781B2 (ja) 2015-05-20
CA2949515A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
SMT201400161B (it) Nuove forme poliformiche di sale di idrocloruro di3-(1-[[3-[5-1-metil-piperidin-4il metossi)-pirimidin-2-il]-benzil]]-6-osso-1,6-didro-piridazin-3-il-benzonitrile e procedimenti per la sua produzione
FIC20200037I1 (fi) Otsanimodi tai sen farmaseuttisesti hyväksyttävä suola, erityisesti otsanimodihydrokloridi
IL214178A0 (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine
BRPI0923176A2 (pt) salde hemifumarato de ácido 1-[4-[1-(4-ciclo-hexil-3 trifluorometilbenzilóxi-imino)-etil]-2etil-benzil]-azetidina-3-carboxílio.
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
SI2182949T1 (sl) (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciklo(2.2.2)okt-3-il)benzofuran -2-karboksamid, nove oblike soli in postopki za njihovo uporabo
HRP20190398T1 (hr) Čvrsti oblik (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidroklorida
IL291738A (en) Production method for 1-(4-(4-(4,3-dichloro-2-fluorophenylamino)-7-methoxyquinazoline-6-yloxy-piperidin-1-yl)-prop-2-en-1-one hydrochloride and intermediates used for this
DK2200985T3 (da) 1,3-Disubstituerede 4-(aryl--X-phenyl)-1H-pyridin-2-oner
PL3835297T3 (pl) Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu
IT1395416B1 (it) Materasso di gel e procedimento per la sua produzione.
DK2445883T3 (da) Heterocykliske sulfonamider, anvendelser og farmaceutiske sammensætniger deraf
DK2368118T3 (da) Biomarkører til inhibitorer med anti-angiogen aktivitet
EP2504776A4 (en) DENSITY-BASED CLUSTERING FOR MULTI-DIMENSIONAL DATA
BRPI0915786A2 (pt) placa de lingotamento contínuo e método para sua produção
FI20086024A0 (fi) Uusi farmaseuttinen tuote
DE112007002501A5 (de) Doppelkeilverklotzung für Fensterflügel
IT1400355B1 (it) Elemento di rivestimento, e procedimento per la sua realizzazione
FR2924340B1 (fr) Procede de maquillage des ongles.
FR2927546B1 (fr) Procede transcritique
EP2379676A4 (en) LOW PRESSURE FISCHER-Tropsch PROCEDURE
IT1399606B1 (it) Zoccolino preadesivizzato e macchina per la sua produzione
IT1394177B1 (it) Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
IT1392711B1 (it) Complesso di persiana ed inferriata per serramenti di edificio.
ITCZ20090002A1 (it) Telaio per porte reversibile